Citifinancial Lending, Inc. – Trademark Portfolio
Entity Type: 03
Citifinancial Lending, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 2 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MESODERM RX. The owner is based in Pembroke Pines, FL.
1271 Nw 137 Avenue
Pembroke Pines, FL 33028
Showing of trademarks Trademarks
Trademark Classifications
Citifinancial Lending, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Citifinancial Lending, Inc. have?
Citifinancial Lending, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Citifinancial Lending, Inc. file in?
Citifinancial Lending, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 16 (Paper Goods), Class 5 (Pharmaceuticals). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Citifinancial Lending, Inc.'s most well-known trademarks?
Citifinancial Lending, Inc.'s registered trademark portfolio includes well-known marks such as MESODERM RX. These are among 2 currently registered trademarks in the portfolio.
What is Citifinancial Lending, Inc.'s trademark registration success rate?
Citifinancial Lending, Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.